C-3GJZNeuroClues
eye-tracking, neurological biomarkers, AI
diagnostics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-3GJZ
C-3GJZC-3GJZeye-tracking, neurological biomarkers, AI
0-100 chain-logic scale · 15 dimensions · scored on public evidence
NeuroClues eye-tracking, neurological biomarkers, AI
NeuroClues develops an eye-tracking environment that helps practitioners quantify neurological clinical exams using non-invasive biomarkers. The site says its product is CE-marked as a Class IIa medical device in the European Union and is intended to support diagnosis, patient follow-up, and research. The company is powered by P3Lab SRL and lists support from the Walloon Region and the European Innovation Council.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
NeuroClues — Near-term readout · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: approved. Band: near_readout. Modifiers: +5 depth (2 programs at approved).…
Source: Deterministic